Referenties

  1. R. Lovell et al. Global Prevalence of an Risk Factors for Irritable Bowel Syndrome: A Meta-Analysis Clinical gastroenterology and Hepatology 2012;10:712-721.

  2. Van den Houte K et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J. 2019 Mar;7(2):307-315. doi: 10.1177/2050640618821804. Epub 2018 Dec 22. PMID: 31080615; PMCID: PMC6498809.

  3. Gebruiksaanwijzing Gelsectan®

  4. T. Piche Tight junctions and IBS – the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil (2014) 26, 296-302.

  5. Agnieszka Kosinska et al. Interactions between tannins and proteins isolated from broad bean seeds (Vicia faba Major) yield soluble and non-soluble complexes Eur Food Res Technol (2011) 233:213–222 DOI 10.1007/s00217-011-1506-9.

  6. J. Bian et al. Structural features and antioxidant activity of xylooligosaccharides enzymatically produced from sugarcane bagasse. Bioresour Technol. 2013 Jan;127:236-41. doi: 10.1016/j.biortech.2012.09.112. Epub 2012 Oct 6. PMID: 23131647.

  7. J. Wang et al. Wheat bran xylooligosaccharides improve blood lipid metabolism and antioxidant status in rats fed a high-fat diet, Carbohydrate Polymers, Volume 86, Issue 3, 2011, Pages 1192-1197, ISSN 0144-8617, https://doi.org/10.1016/j.carbpol.2011.06.014. (https://www.sciencedirect.com/science/article/pii/S0144861711004747).

  8. C. Yang et al. Effects of dietary oligosaccharides on serum biochemical index, intestinal morphology, and antioxidant status in broilers. Anim Sci J. 2022 Jan- Dec;93(1):e13679. doi: 10.1111/asj.13679. PMID: 35068019.

  9. C. Huang et al. A sustainable process for procuring biologically active fractions of high-purity xylooligosaccharides and water-soluble lignin from Moso bamboo prehydrolyzate. Biotechnol Biofuels 12, 189 (2019). https://doi.org/10.1186/s13068-019-1527-3.

  10. Trifan A. et al. Efficacy and safety of Gelsectan® for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial, United European Gastroenterology Journal 2019, Vol. 7(8):1093-1101.

Dit materiaal werd opgemaakt op 2 juli 2024 - GEL/24/003/NL

Gelsectan